Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ACE2-mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Capital Medical University
- Modality
- Stem Cell Therapies → Cell Therapies, Gene Therapies
- Administration
- Intravenous
01
Overview
ACE2-mesenchymal stem cells are genetically engineered mesenchymal stem cells that overexpress angiotensin-converting enzyme 2, typically generated by lentiviral transduction of bone marrow-derived or umbilical cord-derived MSCs. This investigational **cell therapy** is being studied mainly for severe inflammatory lung disease such as COVID-19 pneumonia, acute lung injury, and acute respiratory distress syndrome. The therapeutic rationale is to enhance local ACE2 activity within the renin-angiotensin system, promoting conversion of angiotensin II to angiotensin 1-7 and thereby reducing inflammation, vascular permeability, cell death, and cytokine-driven lung damage. Available public information points to academic clinical development in China, including work at Beijing YouAn Hospital of Capital Medical University, rather than a clearly identified commercial branded product.
- Other names
- ACE2-MSCsACE-2-MSCsACE 2-MSCsACE2-overexpressing mesenchymal stem cellsACE-2-overexpressing mesenchymal stem cellsACE 2-overexpressing mesenchymal stem cellsACE2 gene-modified mesenchymal stem cellsACE-2 gene-modified mesenchymal stem cellsACE 2 gene-modified mesenchymal stem cells
Beyond the preview
Go deeper on ACE2-mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ACE2-mesenchymal stem cells.